TAVR is a go-to treatment for symptomatic severe aortic stenosis in much of the world, thanks in large part to the hard work of research teams that never stop looking for new, innovative ways to make the technology more effective.

TAVR procedures have surged more than 30% since 2020, with more than 107,000 patients receiving a new prosthetic valve in 2023 alone. As this trend continues, it’s increasingly important that cardiologists consider the long-term impact on future coronary interventions patients may need.  

Self-expanding and balloon-expandable TAVR valves are associated with comparable success rates and one-year outcomes when treating type 1 bicuspid aortic stenosis. However, each valve type comes with its own advantages and disadvantages.

Medtronic has launched new research into AI's potential to identify patients with severe aortic stenosis and other worrying symptoms. The company hopes to overcome longstanding health disparities and reach individuals who may otherwise go untreated.

TAVR patients in this study were treated with early-generation devices that have since been updated, but researchers still believe their data are relevant to today's care teams.

Researchers took a closer look at the effectiveness of redo TAVR, implanting Sapien 3 valves into a variety of explanted CoreValve and Evolut valves.

Treating patients younger than 65 with TAVR is associated with certain risks for heart teams to consider. Fortunately, researchers found, care teams appear to be choosing patients wisely. 

Demand for inpatient and outpatient cardiology services is expected to increase significantly in the next decade, putting hospitals and health systems in a position where they need to plan ahead or risk falling behind.